LCZ696 THERAPY IS ASSOCIATED WITH IMPROVEMENT OF VENTRICULAR ARTERIAL COUPLING AND WORK EFFICIENCY IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

被引：0
|
作者：
Kobalava, Z. [1 ]
Babaeva, L. [1 ]
Lukina, O. [1 ]
Zharikova, E. [1 ]
Tyukhmenev, E. [1 ]
Villevalde, S. [1 ]
机构：
[1] PFUR, Moscow, Russia
来源：
JOURNAL OF HYPERTENSION | 2016年 / 34卷
关键词：
D O I：
10.1097/01.hjh.0000492025.22857.94
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
PP.20.01
引用
收藏
页码：E239 / E239
页数：1
相关论文
共 50 条
  • [21] SACUBITRIL/VALSARTAN THERAPY IMPROVES VENTRICULAR-ARTERIAL COUPLING IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
    Kobalava, Z.
    Villevalde, S.
    Lukina, O.
    Babaeva, L.
    Meray, I.
    JOURNAL OF HYPERTENSION, 2017, 35 : E295 - E295
  • [22] Ventricular-arterial coupling is associated with NT-proBNP in stable patients with heart failure and reduced ejection fraction
    Akhmetov, R.
    Villevalde, S.
    Safarova, A.
    Moiseev, V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S323 - S323
  • [23] Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
    Masarone, Daniele
    Errigo, Vittoria
    Melillo, Enrico
    Valente, Fabio
    Gravino, Rita
    Verrengia, Marina
    Ammendola, Ernesto
    Vastarella, Rossella
    Pacileo, Giuseppe
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 10
  • [24] Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
    Lavall, Daniel
    Stegmann, T.
    Parentin, L.
    Hagendorff, A.
    Schirmer, S. H.
    Laufs, U.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 51 - 51
  • [25] How many patients with chronic heart failure will be eligible for LCZ696 in the community?
    Pellicori, P. Pierpaolo
    Urbinati, A.
    Shah, P.
    Macnamara, A.
    Kazmi, S.
    Dierckx, R.
    Cleland, J. G. F.
    Clark, A. L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 235 - 235
  • [26] New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?
    Athyros, Vasilios G.
    Katsiki, Niki
    Karagiannis, Asterios
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (06) : 867 - 869
  • [27] THE EFFICACY OF THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR, LCZ696, IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IS INDEPENDENT OF BLOOD PRESSURE LOWERING.
    Jhund, Pardeep
    Claggett, Brian
    Packer, Milton
    Zile, Michael
    Voors, Adriaan
    Pieske, Burkert
    Lefkowitz, Martin
    Shi, Victor
    Bransford, Toni
    McMurray, John
    Solomon, Scott
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A812 - A812
  • [28] Effects of LCZ696 on lipid metabolism in an animal model of heart failure with preserved ejection fraction (HFpEF). Possible implications for the management of obesity associated with HFpEF
    Morana Fernandez, S.
    Otero, O.
    Feijoo Bandin, S.
    Anido Varela, L.
    Abuin Vazquez, X.
    Aragon Herrera, A.
    Campos Toimil, M.
    Rodrigues, A.
    Goncalves, A.
    Morais, J.
    Alves, I. N.
    Sousa Mendes, C.
    Falcao Pires, I.
    Gonzalez Juanatey, J. R.
    Lago, F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 631 - 632
  • [29] Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
    Liu, Dan
    Hu, Kai
    Schregelmann, Lena
    Hammel, Clara
    Lengenfelder, Bjorn Daniel
    Ertl, Georg
    Frantz, Stefan
    Nordbeck, Peter
    ESC HEART FAILURE, 2023, 10 (02): : 1358 - 1371
  • [30] Effects of valsartan/sacubitril on parameters of ventricular-arterial coupling in patients with heart failure and reduced ejection fraction
    Kobalava, Z.
    Villevalde, S.
    Tyukhmenev, E.
    Lukina, O. Olga
    Babaeva, L.
    Zharikova, E.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 47 - 47
12345